MedTrace Logo

Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLC

NCT06827145 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-02-14

No results posted yet for this study

Summary

This is a Prospective, open label, single arm study to evaluate the efficacy and safety of Vebreltinib combined with Osimertinib in the treatment of locally advanced or metastatic non-small cell lung cancer with EGFR 21 L858R mutation

Conditions

  • Non-Small-Cell Lung Cancer

Interventions

DRUG

Vebreltinib

Vebreltinib 100mg oral BID

DRUG

Osimertinib

Osimertinib 80mg oral once daily.

Sponsors & Collaborators

  • Avistone Biotechnology Co., Ltd.

    collaborator INDUSTRY

  • National Cancer Center, China

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-14
Primary Completion
2026-09-30
Completion
2028-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06827145 on ClinicalTrials.gov